IBio Inc. (NYSEAMERICAN: IBIO) Announces Immune Response in Preclinical Studies of the IBIO-201 COVID-19 Vaccine Program

The COVID-19 pandemic is an extraordinary global public health crisis. It has continued to raise a sense of urgency to develop safe and effective treatments, which can stop the rapid spread of infections. Companies, scientists, and researchers have come together to seek a possible vaccine for the pandemic. IBio Inc. (NYSEAMERICAN:IBIO), which has investigated an array of adjuvants, has provided an update on one of its patented vaccine candidates; the IBIO-201.

The company says it has completed about ten preclinical arms of study for the antigen-adjuvant combinations. The study’s goal was to produce a safe and effective vaccine for COVID-19 disease, the primary target being the elderly, one of the most vulnerable populations.

IBIO-201 Demonstrated an Ability to Generate an Immune Response

iBio is still seeking to gain more insight as it looks forward to completing data analysis of the COVID-19 vaccine candidate. Earlier preclinical data already demonstrated the vaccine’s ability to generate an immune response to SARS-CoV-2 sequences. This means it can neutralize protein interaction.

In the early functional testing, IBIO-201 was immunized on mice. The result was a demonstration of the presence of antibodies. These are reportedly interferences in the binding of SARS-CoV-2 spike protein sequences to humans. Nonetheless, iBio has unveiled a continued interest in additional testing of IBIO-201. This will include further evaluations of neutralizing titers in multiple formats as well as significant immune profiling studies

A collaboration with the Texas A&M University System (“TAMUS”) laboratories

The SARS-Cov2 virus is not only unusually tough on the immune systems for the elderly but also people with chronic health problems. Under the leadership of Dr. James Samuel, a regents’ professor, a team of scientists at Texas A&M University College of Medicine has congregated and will be working on two COVID-19 vaccine candidates.

The University is collaborating with iBio Inc to test the vaccines, which could be mass-produced through a plant-based growing system called “FastPharming.” This initiative is established in factories to enhance rapid delivery and medical countermeasures in response to a pandemic.